Drug Makers Ask JPML to Centralize 30 Federal Plavix Actions

WASHINGTON, D.C. — Bristol-Meyers Squibb Co. (NYSE: BMY) and Sanofi-Aventis U.S. LLC have renewed their motion for centralization of 30 federal Plavix product liability and marketing cases, plus all such future Plavix cases, for coordinated pretrial proceedings.

“Although the panel denied defendants’ motion to centralize in 2011, the litigation is not dramatically different in size and kind,” the drug makers assert in their Oct. 15 motion. “Plavix litigation has now become a significant mass tort that demands coordination. Multiple plaintiffs’ counsel have filed product liability lawsuits on behalf of thousands of plaintiffs in state and federal courts around the country.”